https://www.dovepress.com/feed/journal/101New articles released by Dove Press for Blood and Lymphatic Cancer: Targets and Therapyen-us2026, Dove Pressangela@dovepress.com (Angela Jones)Dove Press Blood and Lymphatic Cancer: Targets and Therapyhttps://www.dovepress.com/feed/journal/101https://www.dovepress.com/assets/img/addon/rss-banner.jpg140140https://www.dovepress.com/short-term-longitudinal-analysis-of-gut-microbiota-dynamics-during-ant-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyFri, 01 May 2026 19:15:00 +1200https://doi.org/10.2147/BLCTT.S598958https://www.dovepress.com/poor-outcome-of-pediatric-patients-with-acute-lymphoblastic-leukemia-h-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyThu, 30 Apr 2026 03:55:00 +1200https://doi.org/10.2147/BLCTT.S592290https://www.dovepress.com/defining-high-risk-disease-biology-in-multiple-myeloma-a-narrative-rev-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyMon, 27 Apr 2026 18:45:00 +1200https://doi.org/10.2147/BLCTT.S586948https://www.dovepress.com/enzymatic-laccase-nanoreactors-induce-apoptosis-in-molt-4-all-cells-an-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyMon, 27 Apr 2026 13:45:00 +1200https://doi.org/10.2147/BLCTT.S576292https://www.dovepress.com/venetoclax-plus-hypomethylating-agents-for-treatment-nave-myelodysplas-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyFri, 24 Apr 2026 21:40:00 +1200https://doi.org/10.2147/BLCTT.S592550https://www.dovepress.com/prognostic-value-of-the-aggregate-inflammation-systemic-index-aisi-in--peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyTue, 31 Mar 2026 06:42:00 +1300https://doi.org/10.2147/BLCTT.S571663https://www.dovepress.com/crosstalk-between-foxn3-and-e2f5-reveals-a-novel-tumor-suppressive-pat-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyTue, 24 Mar 2026 23:45:00 +1300https://doi.org/10.2147/BLCTT.S571966https://www.dovepress.com/health-disparities-in-acute-myeloid-leukemia-patients-undergoing-treat-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyThu, 12 Mar 2026 19:30:00 +1300https://doi.org/10.2147/BLCTT.S559759https://www.dovepress.com/construction-and-validation-of-an-n7-methylguanosinerelated-prognostic-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 11 Mar 2026 20:30:00 +1300https://doi.org/10.2147/BLCTT.S575337https://www.dovepress.com/association-between-petroleum-compounds-exposure-and-risk-of-childhood-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 11 Feb 2026 00:20:00 +1300https://doi.org/10.2147/BLCTT.S571340https://www.dovepress.com/natural-killert-cell-lymphoma-associated-hemophagocytic-lymphohistiocy-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyTue, 27 Jan 2026 00:00:00 +1300https://doi.org/10.2147/BLCTT.S574445https://www.dovepress.com/safety-and-efficacy-of-flumatinib-in-patients-with-chronic-phase-chron-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyThu, 22 Jan 2026 00:00:00 +1300https://doi.org/10.2147/BLCTT.S573070https://www.dovepress.com/study-on-the-role-of-neutrophil-extracellular-traps-based-risk-model-a-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyTue, 13 Jan 2026 00:00:00 +1300https://doi.org/10.2147/BLCTT.S562651https://www.dovepress.com/global-patterns-temporal-trends-and-potential-non-infectious-risk-fact-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyThu, 08 Jan 2026 00:00:00 +1300https://doi.org/10.2147/BLCTT.S556459https://www.dovepress.com/expression-and-clinical-significance-of-bcl2-interacting-protein-3-lik-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 17 Dec 2025 22:55:00 +1300https://doi.org/10.2147/BLCTT.S557238https://www.dovepress.com/lrg1-drives-aml-progression-by-disrupting-myeloid-progenitor-regulatio-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 17 Dec 2025 03:05:00 +1300https://doi.org/10.2147/BLCTT.S556618https://www.dovepress.com/alantolactone-inhibits-double-expression-lymphoma-via-dual-targeted-gl-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyFri, 12 Dec 2025 22:15:00 +1300https://doi.org/10.2147/BLCTT.S556751https://www.dovepress.com/phase-ii-trial-of-an-orelabrutinib-based-combination-therapy-in-newly--peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapySat, 06 Dec 2025 23:10:00 +1300https://doi.org/10.2147/BLCTT.S556657https://www.dovepress.com/venetoclax-plus-blinatumoma-as-first-line-therapy-for-newly-diagnosed--peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 05 Nov 2025 04:50:00 +1300https://doi.org/10.2147/BLCTT.S556608https://www.dovepress.com/the-ongoing-challenges-of-managing-cytopenic-myelofibrosis-in-2025-the-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 24 Sep 2025 23:35:00 +1200https://doi.org/10.2147/BLCTT.S549533https://www.dovepress.com/comprehensive-analysis-of-tumor-microenvironment-and-pd-l1-expression--peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapySat, 06 Sep 2025 17:00:00 +1200https://doi.org/10.2147/BLCTT.S545717https://www.dovepress.com/comprehensive-evaluation-of-drug-related-problems-and-pharmacotherapy--peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyThu, 04 Sep 2025 03:55:00 +1200https://doi.org/10.2147/BLCTT.S538606https://www.dovepress.com/serum-atic-expression-as-a-novel-diagnostic-and-prognostic-biomarker-i-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapySat, 30 Aug 2025 00:05:00 +1200https://doi.org/10.2147/BLCTT.S537524https://www.dovepress.com/neutrophil-related-genes-predict-prognosis-and-contribute-to-immunosup-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyMon, 18 Aug 2025 19:25:00 +1200https://doi.org/10.2147/BLCTT.S529074https://www.dovepress.com/optimizing-timing-and-preparation-for-allogeneic-hematopoietic-stem-ce-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyFri, 01 Aug 2025 17:35:00 +1200https://doi.org/10.2147/BLCTT.S527790https://www.dovepress.com/clinical-characteristics-prognostic-risk-factors-and-primary-treatment-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyMon, 07 Jul 2025 20:55:00 +1200https://doi.org/10.2147/BLCTT.S529249https://www.dovepress.com/deep-dive-into-targeted-therapies-understanding-idh1-mutant-aml-treatm-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 02 Jul 2025 21:15:00 +1200https://doi.org/10.2147/BLCTT.S549780https://www.dovepress.com/advancing-aml-treatment-evidence-based-regimens-and-guideline-updates--peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyWed, 02 Jul 2025 21:10:00 +1200https://doi.org/10.2147/BLCTT.S548242https://www.dovepress.com/advancing-leukemia-diagnosis-and-treatment-who-supported-laboratory-in-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapyTue, 24 Jun 2025 21:05:00 +1200https://doi.org/10.2147/BLCTT.S518005https://www.dovepress.com/unveiling-the-mysteries-of-molecular-testing-in-aml-a-guide-for-oncolo-peer-reviewed-fulltext-article-BLCTTBlood and Lymphatic Cancer: Targets and TherapySat, 21 Jun 2025 20:05:00 +1200https://doi.org/10.2147/BLCTT.S543541